Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Blue Cross of California Incorporated et al v. Insys Therapeutics Incorporated
Case Number:
2:17-cv-02286
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
April 04, 2019
Insys Wants Anthem Fentanyl Suit Sent To Ohio Opioid MDL
Insys Therapeutics Inc. has asked an Arizona federal judge to freeze Anthem's suit alleging Insys bribed doctors to overprescribe painkillers, arguing that newly added claims mean ongoing multidistrict opioid litigation is the right venue for the case.
-
December 17, 2018
Anthem Nabs Fees To Sanction Insys In $19M Fentanyl Fight
Insys Therapeutics Inc. has been sanctioned by an Arizona federal court for failing to prepare a witness who was supposed to answer questions about why employees replaced the word "cancer" with an exclamation point in emails, in Blue Cross Blue Shield's suit alleging that the embattled opioid maker bribed doctors to overprescribe its flagship painkiller, Subsys.
-
December 13, 2018
Insys Slams BCBS Privilege Claim In $19M Fentanyl Suit
Fentanyl maker Insys Therapeutics Inc. has filed a blistering request in Arizona federal court to wrest documents from Blue Cross Blue Shield over the insurer's allegations that Insys conjured up $19 million worth of bogus prescriptions for the powerful opiate, calling the insurer's attorney-client privilege claims a fiction.
-
September 17, 2018
Insys Wants Out Of Off-Label Fentanyl Prescription Suit
Insys Therapeutics Inc. has urged an Arizona federal court to toss a suit from several Blue Cross Blue Shield Association units that have accused Insys of bribing physicians to write off-label prescriptions for its fentanyl spray.
-
July 14, 2017
BCBS Units Sue Insys Over Off-Label Fentanyl Rx Scheme
Several Blue Cross Blue Shield Association units have accused Insys Therapeutics Inc. in Arizona federal court of bribing physicians to write off-label prescriptions for its Fentanyl spray, causing the insurers to shell out millions of dollars in unnecessary reimbursements.